Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis

The purpose of this study is to determine whether apremilast is safe and effective for treating patients with psoriatic arthritis.

Study Overview

• Status: Completed
• Conditions: Psoriatic Arthritis
• Intervention / Treatment: Drug: Apremilast 30 mg; Drug: Placebo

Detailed Description

This is a Phase 3b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of apremilast monotherapy in subjects with active psoriatic arthritis.

Approximately 214 subjects will be randomized in a 1:1 ratio to either apremilast 30 mg BID (twice a day) or identically-appearing placebo, with approximately 107 subjects per treatment group.

This is a 113-week study. The subjects will spend 24 weeks in the double-blind, placebo-controlled treatment phase, followed by 28 weeks of active treatment phase (ie, up to Week 52 visit). The original treatment assignments (apremilast 30 mg BID (twice a day) or placebo) will remain blinded until all subjects have completed their Week 52 visit (or have discontinued). After the Week 52 visit, all subjects in the extension phase will continue to receive treatment with apremilast 30 mg BID (twice a day) until the end of the study (ie, up to Week 104 visit) or until early discontinuation from the trial.

The study will consist of 5 phases:

1. Screening Phase - up to 5 weeks
2. Randomized, Placebo-controlled, Double Blind Treatment Phase - Weeks 0 to 24
3. Active Treatment Phase - Week 24 to Week 52
4. Open-label Extension Phase - Week 52 to Week 104
5. Post-treatment Observational Follow-up Phase

• Study Type: Interventional
• Enrollment (Actual): 219
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • Box Hill, Australia, 3128
    • Eastern Health Clinical School
  • Camperdown, Australia, 2050
    • Royal Prince Alfred Hospital
  • Hobart,, Australia, 7000
    • Menzies Centre for Population Health Research
  • Kogarah, Australia, 2217
    • Optimus Clinical Research Pty. Ltd
  • Maroochydore, Australia, 4558
    • Coastal Joint Care
  • Westmead, NSW, Australia, 2145
    • Westmead Cancer Care Center
  • Western Australia
    • Victoria Park, Western Australia, Australia, 6100
      • Colin Bayliss Research and Teaching Unit
• Canada
  • Quebec, Canada, G1V 4G2
    • CHUL du CHU de Québec
  • British Columbia
    • Vancouver, British Columbia, Canada, V6J 1S3
      • Manna Research
  • Manitoba
    • Winnipeg, Manitoba, Canada, R3A1M3
      • Manitoba Clinic
  • Newfoundland and Labrador
    • Saint John's, Newfoundland and Labrador, Canada, A1A 4Y3
      • Karma Clinical Trials
    • St John's, Newfoundland and Labrador, Canada, A1A 5E8
      • Nexus Clinical Research
  • Ontario
    • Hamilton, Ontario, Canada, L8N 2B6
      • MAC Research Incorporated
    • Toronto, Ontario, Canada, M9W4L6
      • Manna Research
    • Toronto, Ontario, Canada, M9C 5N2
      • Arthur Karasik Private Practice
    • Windsor, Ontario, Canada, N8X 5A6
      • Jude Rodrigues Private Practice
• Czechia
  • Praha 2, Czechia, 128 50
    • Revmatologicky ustav
  • Praha 4, Czechia, 140 00
    • Revmatologicka ambulance
  • Sokolov, Czechia, 356 01
    • Revmatologicka ambulance
  • Zlin, Czechia, 760 01
    • PV - MEDICAL, s.r.o.
• Estonia
  • Tallinn, Estonia, EE-11412
    • East Tallinn Central Hospital
  • Tallinn, Estonia, EE-10117
    • Innomedica Medical and Research Centre
  • Tartu, Estonia, 50106
    • Clinical Research Centre Ltd
• Hungary
  • Budapest, Hungary, 1036
    • Qualiclinic Kft
  • Debrecen, Hungary, 4032
    • Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum
  • Szolnok, Hungary, 5000
    • MAV Korhaz es Rendelointezet Szolnok
  • Veszprém, Hungary, 8200
    • Veszprém Megyei Önkormányzat Csolnoky Ferenc Kórház-Rendelöintézet
• New Zealand
  • Hamilton, New Zealand, 3204
    • Waikato Hospital
  • Manukau, New Zealand, 1640
    • Middlemore Clinical Trials
  • Timaru, New Zealand, 8601
    • Timaru Hospital
• Romania
  • Bucharest, Romania, 011172
    • Sf. Maria Clinical Hospital
  • Cluj-Napoca, Romania, 400006
    • Emergency County Clinical Hospital
  • Galati, Romania, 800578
    • Sf Apostol Andrei Emergency Clinical County Hospital
  • Sfantu Gheorghe, Covasna, Romania, 520052
    • SC Covamed SRL
• Russian Federation
  • Kazan, Russian Federation, 420103
    • Research Medical Complex Vashe Zdorovie
  • Penza, Russian Federation, 440026
    • Penza Regional Clinical Hospital n.a. N.N. Burdenko
  • Smolensk, Russian Federation, 214025
    • Departmental Hospital at Smolensk Station RZhD JSC
  • Yaroslavl, Russian Federation, 150062
    • Yaroslavl Regional Clinical Hospital
• Spain
  • A Coruña, Spain, 15006
    • Hospital Universitario A Coruña
  • Barcelona, Spain, 08035
    • Hospital Vall d'Hebron
  • Barcelona, Hospitalet De Llobregat, Spain, 08907
    • Hospital Universitari de Bellvitge
  • Bilbao, Spain, 48013
    • Hospital de Basurto-Osakidetza
  • La Laguna, Spain, 38320
    • Hospital Universitario de Canarias
  • Madrid, Spain, 28046
    • Hospital Universitario La Paz
  • Málaga, Spain, 29009
    • Hospital General Carlos Haya
  • Sabadell, Spain, 08208
    • Corporacion Sanitaria Parc Tauli
  • Santiago de Compostela, Spain, 15706
    • Hospital Clinico Universitario de Santiago
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35216
      • Achieve Clinical Research LLC
  • California
    • Palm Desert, California, United States, 92260
      • Desert Medical Advances
  • Florida
    • Brandon, Florida, United States, 33511
      • Bay Area Arthritis and Osteoporosis
    • Brandon, Florida, United States, 33511
      • Health Point Medical Group
    • Hialeah, Florida, United States, 33016
      • Palmetto Medical Research
    • Naples, Florida, United States, 34102
      • Jeffrey Alper MD Research
    • New Port Richey, Florida, United States, 34652
      • Suncoast Clinical Research
    • Tampa, Florida, United States, 33612-4799
      • University of South Florida
  • Idaho
    • Coeur d'Alene, Idaho, United States, 83814
      • Coeur D'Alene Arthritis Clinic
  • Illinois
    • Rockford, Illinois, United States, 61107
      • Rockford Orthopedic Associates, LLC
  • Michigan
    • Lansing, Michigan, United States, 48910
      • Advanced Rheumatology
  • Montana
    • Kalispell, Montana, United States, 59901
      • Research West Incorporated
  • Nebraska
    • Omaha, Nebraska, United States, 68134
      • Heartland Clinical Research, Inc.
  • North Carolina
    • Greenville, North Carolina, United States, 27834
      • Physicians East
    • Winston-Salem, North Carolina, United States, 27103-3914
      • Piedmont Medical Research Associates Inc
  • Pennsylvania
    • Duncansville, Pennsylvania, United States, 16635
      • Altoona Center For Clinical Research
  • Tennessee
    • Jackson, Tennessee, United States, 38305
      • West Tennessee Research Institute
    • Memphis, Tennessee, United States, 38119
      • Ramesh C Gupta MD
  • Texas
    • Austin, Texas, United States, 78731
      • Austin Regional Clinic
    • Dallas, Texas, United States, 75231
      • Baylor Research Institute
    • Houston, Texas, United States, 77090
      • Houston Medical Research
    • Lubbock, Texas, United States, 79424
      • Arthritis and Osteoporosis Associates LLP
  • Utah
    • Salt Lake City, Utah, United States, 84132
      • University of Utah
  • West Virginia
    • Clarksburg, West Virginia, United States, 26301
      • Mountain State Clinical Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Males or females, 18 years and older at time of consent.
2. Must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
3. Able to adhere to the study visit schedule and other protocol requirements.
4. Have a documented diagnosis of psoriatic arthritis (by any criteria) of at least 3 months' duration
5. Meet the classification criteria for psoriatic arthritis (CASPAR) at the time of screening.
6. Have at least 3 swollen AND at least 3 tender joints.
7. Must have high sensitivity C-Reactive Protein (hs-CRP) of at least 0.5 mg/dL at screening and at baseline.
8. Must be receiving treatment on an outpatient basis.
9. Must be tumor necrosis factor (TNF) blocker naive and other Biologic naïve for dermatologic and rheumatic conditions
10. Subjects taking disease modifying anti-rheumatoid drugs (DMARDs), with the exception of cyclosporine and leflunomide (see 7.3. Exclusion Criteria 20, 21), do not require a washout, however, they must discontinue the DMARD treatment at least one day prior to their baseline visit (ie, Visit 2, Day 0)
11. Subjects who have been previously treated with leflunomide will require a 12-week washout or treatment with the cholestyramine, per leflunomide prescribing label (ie. 8 g cholestyramine 3 times daily for 11 days.
12. Subjects who have been previously treated with cyclosporine will require a 4-week washout prior to randomization to participate in the study
13. If taking oral corticosteroids, must be on a stable dose of prednisone less than or equal to 10 mg/day or equivalent for at least 30 days prior to baseline visit (ie, Day 0)
14. If taking nonsteroidal anti-inflammatory drugs (NSAIDs) or narcotic analgesics, must be on stable dose for at least 30 days prior to baseline visit (ie, Day 0) and until they have completed the Week 24 study visit.

15. Must meet the following laboratory criteria:

    • White blood cell count greater than 3000/mm^3 (greater than 3.0 X 10^9/L) and less than 14,000/mm^3 (less than 14 X 10^9/L)
    • Platelet count at least 100,000/mm^3 (at least 100 X 10^9/L)
    • Serum creatinine less than or equal to 1.5 mg/dL (less than or equal to 132.6 μmol/L)
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to twice upper limit of normal (ULN). If initial test shows ALT or AST greater than 2 times the ULN, one repeat test is allowed during the screening period.
    • Total bilirubin less than or equal to 2 mg/dL (less than or equal to 34 μmol/L) or Albumin greater than LLN. If initial test result is greater than 2 mg/dL, one repeat test is allowed during the screening period.
    • Hemoglobin at least 9 g/dL (at least 5.6 mmol/L)
    • Hemoglobin A1c less than or equal to 9.0%

16. All females of childbearing potential (FCBP) must use one of the approved contraceptive options as described below while on investigational product and for at least 28 days after administration of the last dose of the investigational product.

    At the time of study entry, and at any time during the study when a female subject of childbearing potential's contraceptive measures or ability to become pregnant changes, the investigator will educate the subject regarding contraception options and the correct and consistent use of effective contraceptive methods in order to successfully prevent pregnancy.

    Females of childbearing potential must have a negative pregnancy test at Screening and Baseline. All FCBP subjects who engage in activity in which conception is possible must use one of the approved contraceptive options described below:

    Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom (latex condom or non latex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.

17. Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (male latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]) while on investigational product and for at least 28 days after the last dose of investigational product.

Exclusion Criteria:

1. History of clinically significant (as determined by the investigator) cardiac, endocrine, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major uncontrolled disease.
2. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
3. Clinically significant abnormality on a 12-lead electrocardiogram (ECG) at Screening.
4. Pregnant or breast feeding.
5. History of allergy to any component of the investigational product.
6. Hepatitis B surface antigen positive at screening.
7. Hepatitis C antibody positive at screening.
8. History of positive human immunodeficiency virus (HIV), or congenital or acquired immunodeficiency (eg, Common Variable Immunodeficiency Disease).
9. Active tuberculosis or a history of incompletely treated tuberculosis.
10. Clinically significant abnormality based upon chest radiograph with at least posterior-anterior (PA) view (the radiograph must be taken within 12 weeks prior to Screening or during the Screening visit). An additional lateral view is strongly recommended but not required.
11. Active substance abuse or a history of substance abuse within 6 months prior to Screening.
12. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening. Any treatment for such infections must have been completed and the infection cured, at least 4 weeks prior to Screening.

13. Malignancy or history of malignancy, except for:

    1. treated [ie, cured] basal cell or squamous cell in situ skin carcinomas;
    2. treated [ie, cured] cervical intraepithelial neoplasia [CIN] or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years.
14. Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.
15. Erythrodermic, guttate, or generalized pustular psoriasis at randomization.
16. Rheumatic autoimmune disease other than PsA, including, but not limited to: systemic lupus erythematosis (SLE), mixed connective tissue disease (MCTD), scleroderma, polymyositis, or fibromyalgia.
17. Functional Class IV, as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis.
18. Prior history of or current inflammatory joint disease other than PsA (eg, gout, reactive arthritis, rheumatoid arthritis (RA), ankylosing spondylitis, Lyme disease).
19. Prior treatment with more than one non-biologic DMARD
20. Use of the following systemic therapy(ies) within 4 weeks of randomization: cyclosporine or other calcineurin inhibitors, corticosteroids exceeding 10 mg daily prednisone equivalent, as well as other oral agents such as retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, tacrolimus.
21. Use of leflunomide within 12 weeks of randomization, unless subject has taken cholestyramine, 8g TID (three times a day) x 11 days after stopping leflunomide.
22. Previous treatment with biologic agents for rheumatic diseases such as, but not limited to: adalimumab, abatacept, canakinumab, etanercept, golimumab, infliximab, rilonacept, certolizumab pegol, or tocilizumab.
23. Previous treatment with biologic agents for dermatologic diseases such as alefacept, anti-TNFs (eg etanercept, adalinumab) or ustekinumab.
24. Previous treatment with tofacitinib, Anti IL-17 agents or secukinumab
25. Previous treatment with any cell depleting therapies, including investigational agents (eg, rituximab, alemtuzumab, ocrelizumab, alemtuzumab, anti-CD4, anti-CD5, anti-CD3, anti-CD19, and anti-CD20).
26. Treatment with intravenous gamma globulin, plasmapheresis, or Prosorba® column
27. Any previous treatment with alkylating agents such as cyclophosphamide or chlorambucil, or with total lymphoid irradiation.
28. Prior treatment with any non-biologic DMARDS other than methotrexate, sulfasalazine, chloroquine, hydroxychloroquine, azathioprine, fumeric acid esters, cyclosporine, or leflunomide
29. Prior treatment with apremilast, or participation in a clinical study, involving apremilast
30. Use of any investigational drug within 4 weeks of randomization, or 5 pharmacokinetic/ pharmacodynamic half lives, if known (whichever is longer).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Apremilast 30 mg; 30 mg Apremilast tablets administered twice daily (BID) for 24 weeks during the double-blind placebo-controlled phase; followed by 30 mg Apremilast BID for 28 weeks of active treatment phase (up to the 52 week visit); original treatment assignments remain blinded until all participants have completed their 52 week visit or have discontinued. After the Wk 52 visit, all participants in the extension phase will continue to receive treatment with apremilast 30 mg BID until the end of the study (ie, up to Week 104 visit) or until early discontinuation from the trial.	Drug: Apremilast 30 mg; 30mg of Apremilast will be orally administered twice daily for 104 weeks; Other Names: CC-10004; Otezla
Placebo Comparator: Placebo; Oral placebo BID during the placebo controlled phase weeks 0 to 24; placebo treated participants whose improvement is <10% in both swollen and tender joint counts at Week 16 are eligible for early escape (based on the measure of clinical benefit from their current treatment as evidenced by improvement (or lack of improvement) in 1) the physician (evaluator's) global assessment (EGA), 2) patients pain (pain NRS), 3) the patient global assessments (PGA), and 4) the health assessment questionnaire disability index (HAQ-DI); Placebo-treated patients who early escape are transitioned to apremilast 30 mg PO BID during the active treatment phase up to their Week 52 visit; all those who complete the 52-week treatment phase will enter an open-label extension phase for an additional 52 weeks or until early discontinuation from the trial.	Drug: Placebo; Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 16	Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: ≥ 20% improvement in 78 tender joint count;; ≥ 20% improvement in 76 swollen joint count; and; ≥ 20% improvement in at least 3 of the 5 following parameters:Patient's self-assessment of pain (measured on a 0 to 10 unit numeric rating scale [NRS]);Patient's global self-assessment of disease activity (measured on a 0 to 10 unit NRS);Physician's global assessment of disease activity (measured on a 0 to 10 unit NRS);Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);C-Reactive Protein (CRP) Those who withdrew early or who did not have sufficient data at Week 16 were counted as non-responders.	Baseline and Week 16

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24	HAQ-DI is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A higher score indicates worse physical functioning, and a negative change from baseline indicates improvement.	Baseline and Week 24
Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) at Week 24	Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: ≥ 20% improvement in 78 tender joint count;; ≥ 20% improvement in 76 swollen joint count; and; ≥ 20% improvement in at least 3 of the 5 following parameters:Patient's self-assessment of pain (measured on a 0 to 10 unit numeric rating scale [NRS]);Patient's global self-assessment of disease activity (measured on a 0 to 10 unit NRS);Physician's global assessment of disease activity (measured on a 0 to 10 unit NRS);Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);C-Reactive Protein (CRP) Those who withdrew early or who did not have sufficient data at Week 16 were counted as non-responders.	Baseline and Week 24
Change From Baseline in the 28-Joint Disease Activity Score Using C-reactive Protein as the Acute-Phase Reactant (DAS28 [CRP]) at Week 24	The DAS28 measures the severity of disease at a specific time and is derived from the following variables: 28 tender joint count; 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee;; C-reactive protein (CRP); Patient's global assessment of disease activity. DAS28 (CRP) scores range from 0 to 9.4. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission. A higher value indicates higher disease activity, and a negative change from baseline indicates improvement.	Baseline and Week 24
Change From Baseline in the Medical Outcomes Short Form Health Survey (SF-36) V2 Physical Function Domain Score at Week 24	The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from baseline score indicates an improvement.	Baseline and Week 24
Change From Baseline in the 36-item SF-36 Physical Component Summary Score at Week 24	The SF-36 (v 2.0) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component summary (PCS) score includes the physical functioning, role physical, bodily pain, and general health domains. Minimum clinically important difference (MCID) for the scale scores, as well as the PCS and MCS, is defined as a 2.5-point improvement (increase) from baseline. The summary scores range from 0 to 100, with lower scores reflecting more disability, and higher scores reflecting less disability and better health. The 8 domains are regrouped into the PCS and MCS scores.	Baseline and Week 24
Change From Baseline in the Duration of Morning Stiffness at Week 24	Morning stiffness was the participant's assessment of how long their morning stiffness lasted after first waking up in the morning, on average, during the previous week. A higher value indicates longer duration, and a negative change from baseline indicates improvement.	Baseline and Week 24
Percentage of Participants With Improved Change in Severity of Morning Stiffness at Week 24	Morning stiffness severity was the participant's assessment of how severe their morning stiffness was after first waking up in the morning, on average, during the previous week. The severity was recorded as none, mild, moderate, moderately severe, or very severe. The response of no improvement includes subjects who had no change or worsened. Improvement is defined as the change from baseline of a more severe assessment to less severe assessment.	Baseline and Week 24
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 16	HAQ-DI is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A higher score indicates worse physical functioning, and a negative change from baseline indicates improvement.	Baseline and Week 16
Change From Baseline in the Disease Activity Score DAS28 (CRP) at Week 16	The DAS28 measures the severity of disease at a specific time and is derived from the following variables: 28 tender joint count; 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee;; C-reactive protein (CRP); Patient's global assessment of disease activity. DAS28 (CRP) scores range from 0 to 9.4. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission. A negative change from baseline indicates improvement.	Baseline and Week 16
Change From Baseline in 36-item Short Form Health Survey (SF-36) V 2 Physical Functioning Domain at Week 16	The SF-36 (v 2.0) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.	Baseline and Week 16
Mean Change From Baseline in the Duration of Morning Stiffness at Week 16	Morning stiffness was the participant's assessment of how long their morning stiffness lasted after first waking up in the morning, on average, during the previous week. A higher value indicates longer duration, and a negative change from baseline indicates improvement.	Baseline and Week 16
Percentage of Participants Whose Severity of Morning Stiffness at Week 16 Improved From Baseline	Morning stiffness severity was the participant's assessment of how severe their morning stiffness was after first waking up in the morning, on average, during the previous week. The severity was recorded as none, mild, moderate, moderately severe, or very severe. Improvement is defined as the change from baseline of a more severe assessment to less severe assessment. Full Analysis Set; Participants who discontinued early prior to Week 16 and those who did not have sufficient data for a definitive determination of response status at Week 16 were counted as non-responders.	Baseline and Week 16
Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Weeks 2, 4, 6, 8, 12 and 20	Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: ≥ 20% improvement in 78 tender joint count;; ≥ 20% improvement in 76 swollen joint count; and; ≥ 20% improvement in at least 3 of the 5 following parameters:Patient's self-assessment of pain (measured on a 0 to 10 unit numeric rating scale [NRS]);Patient's global self-assessment of disease activity (measured on a 0 to 10 unit NRS);Physician's global assessment of disease activity (measured on a 0 to 10 unit NRS);Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);C-Reactive Protein (CRP)	Baseline and at Weeks 2, 4, 6, 8, 12 and 20
Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Weeks 52 and 104	Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: ≥ 20% improvement in 78 tender joint count;; ≥ 20% improvement in 76 swollen joint count; and; ≥ 20% improvement in at least 3 of the 5 following parameters:Patient's self-assessment of pain (measured on a 0 to 10 unit numeric rating scale [NRS]);Patient's global self-assessment of disease activity (measured on a 0 to 10 unit NRS);Physician's global assessment of disease activity (measured on a 0 to 10 unit NRS);Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);C-Reactive Protein (CRP)	Baseline and Weeks 52 and 104
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Weeks 52 and 104	HAQ-DI is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A higher score indicates worse physical functioning, and a negative change from baseline indicates improvement.	Baseline and Weeks 52 and 104
Change From Baseline in the Disease Activity Score (DAS28) at Week 52 and 104	The DAS28 measures the severity of disease at a specific time and is derived from the following variables: 28 tender joint count; 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee;; C-reactive protein (CRP); Patient's global assessment of disease activity. DAS28 (CRP) scores range from 0 to 9.4. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission. A negative change from baseline indicates improvement.	Baseline and Weeks 52 and 104
Change From Baseline in 36-item SF-36 (V2.0) Physical Functioning Domain Score at Weeks 52 and 104	The SF-36 (v 2.0) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.	Baseline and Weeks 52 and 104
Change From Baseline in the Duration of Morning Stiffness at Weeks 52 and 104	Morning stiffness was the participant's assessment of how long their morning stiffness lasted after first waking up in the morning, on average, during the previous week. A higher value indicates longer duration, and a negative change from baseline indicates improvement.	Baseline and Weeks 52 and 104
Percentage of Participants Whose Severity of Morning Stiffness at Week 52 and 104 Improved From Baseline	Morning stiffness severity was the participant's assessment of how severe their morning stiffness was after first waking up in the morning, on average, during the previous week. The severity was recorded as none, mild, moderate, moderately severe, or very severe. Improvement is defined as the change from baseline of a more severe assessment to less severe assessment.	Baseline and Weeks 52 and 104
Number of Participants With Treatment Emergent Adverse Events (TEAE) During the 24 Week Placebo Controlled Phase	A TEAE is an AE with a start date on or after the date of the first dose of Investigational Product (IP). An AE is any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.	Date of first dose of study drug to Week 24; median duration of exposure during placebo controlled phase was 24.14 weeks
Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Apremilast-Exposure Period	A TEAE is an AE with a start date on or after the date of the first dose of Investigational Product (IP). An AE is any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.	Start of lst dose of IP up to week 104: Weeks 0 to104 for those initially randomized to APR 30 mg BID, Weeks 16 -104 for PBO-treated patients who EE to APR at Week 16 and from Weeks 24-104 for PBO-treated patients who transitioned to APR at Week 24

Collaborators and Investigators

• Sponsor: Amgen

Publications and helpful links

General Publications

• Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, Gomez-Reino JJ, Aelion JA; ACTIVE investigators. Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis. 2018 May;77(5):690-698. doi: 10.1136/annrheumdis-2017-211568. Epub 2018 Jan 17.

Study record dates

Study Major Dates

• Study Start (Actual): September 4, 2013
• Primary Completion (Actual): February 25, 2015
• Study Completion (Actual): November 17, 2016

Study Registration Dates

• First Submitted: August 15, 2013
• First Submitted That Met QC Criteria: August 16, 2013
• First Posted (Estimate): August 20, 2013

Study Record Updates

• Last Update Posted (Actual): May 12, 2020
• Last Update Submitted That Met QC Criteria: April 28, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Keywords: Apremilast, Psoriatic Arthritis, PDE4 inhibitor
• Additional Relevant MeSH Terms: Skin Diseases; Joint Diseases; Musculoskeletal Diseases; Skin Diseases, Papulosquamous; Spinal Diseases; Bone Diseases; Spondylarthropathies; Spondylarthritis; Spondylitis; Psoriasis; Arthritis; Arthritis, Psoriatic; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Phosphodiesterase Inhibitors; Phosphodiesterase 4 Inhibitors; Apremilast
• Other Study ID Numbers: CC-10004-PSA-006

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
• IPD Sharing Time Frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
• IPD Sharing Access Criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR